Drug Trial Radar · NCT00829582
Intravenous Dose-Escalation Study With ETI-204 in Adult Volunteers
Last checked: Nov 20, 2026Latest source record: Nov 14, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
45
Planned (sponsor's estimate)
Start
Feb 2009
Primary completion
Jul 2009
Study completion Sep 2009
Sponsor
- Lead sponsor
- Elusys TherapeuticsAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 27, 2009
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Title: Randomized, Placebo-Controlled, Double-Blind, Dose-Escalation Phase I Study of the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Dose of ETI-204 (AnthimTM) Population: This study will determine the safety, tolerability and pharmacokinetics of a single iv dose of ETI-204 in subjects 18 to 50 years of age. Three cohorts will be studied sequentially: subjects receiving 120 mg, 240 mg and 360 mg of ETI-204. The study will be randomized, double-blind, and stratified by gender. Each cohort will contain 15 subjects (including at least four females), twelve who will receive ETI-204 and three who will receive placebo. Study Objectives: To determine the safety, tolerability and pharmacokinetics of ETI-204 following a single intravenous administration.
Conditions
- Healthy Volunteers
Interventions
ETI-204, "Anthim"Drug
single intravenous infusion of 120, 240 or 360 mg of ETI-204
placeboOther
single intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evidence of clinical safety following the infusionTime frame: 42 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Osu, 5084 Graves 333 W Tenth Ave
Columbus, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.